-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Novel Targets in Aggressive Lymphomas

Program: Education Program
Session: Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
Hematology Disease Topics & Pathways:
Biological, antibodies, Diseases, Therapies, Combinations, Adverse Events, DLBCL, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies
Monday, December 7, 2020, 11:25 AM-11:30 AM

Kami J. Maddocks, MD

Ohio State University Hospital, Upper Arlington, OH

Disclosures: Maddocks: Pharmacyclics: Consultancy, Honoraria; Karyopharm: Consultancy; Seattle Genetics: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; BMS: Consultancy, Research Funding; Celgene: Consultancy, Honoraria; ADC Therapeutics, AstraZeneca: Consultancy.

OffLabel Disclosure: will include current tafa+len data which is under review for approval

<< Previous Presentation | Next Presentation